A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: Establishment of normal levels and clinical application in patients with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 97, Issue 7, 2002, Pages 1755-1762

  Peterson, Christer G B ^a,b   Eklund, Elisabeth ^a,b   Taha, Yesuf ^a,b   Raab, Yngve ^a,b   Carlson, Marie ^a,b  

^a Thermo Fisher Scientific   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM DERIVATIVE; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PROTEIN X; LIPOCALIN; MYELOPEROXIDASE; N ACETYL N,N,N TRIMETHYLAMMONIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; FECES ANALYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN STABILITY; REPRODUCIBILITY; ULCERATIVE COLITIS; VALIDATION PROCESS;

EID: 0036318463     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04193-X     Document Type: Article

References (34)

1. Cationic proteins of human granulocytes. II. Separation of the cationic proteins of the granules of leukemic myeloid cells
2. Purification and characterization of a new cationic protein-eosinophil protein-X (EPX)-from granules of human eosinophils
3. Pharmacology of the eosinophil
4. Neutrophil and eosinophil involvement of the small bowel in patients with celiac disease and Crohn's disease: Studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents
5. Challenge with gliadin induces eosinophil and mast cell activation in the jejunum of patients with celiac disease
6. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study
7. Activation of eosinophils in the pathophysiology of ulcerative colitis
8. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease
9. Functional and phenotypical activation of leucocytes in inflamed human colonic mucosa
10. Eosinophil activation in ulcerative colitis: Studies on mucosal release and localization of eosinophil granule constituents
11. Increased fecal eosinophil cationic protein in inflammatory bowel disease
12. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls
13. Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease
14. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease
15. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils
16. Human neutrophil lipocalin (HNL) is a specific granule constituent of the neutrophil granulocyte. Studies in bronchial and lung parenchymal tissue and peripheral blood cells
17. Biochemical and morphological characterization of azurophil and specific granules of human neutrophilic polymorphonuclear leukocytes
18. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion
19. Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis
20. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil-derived proteins
21. Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States
22. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)
23. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis
24. Eosinophil markers in seasonal allergic rhinitis. Intranasal fluticasone propionate inhibits local and systemic increases during the pollen season
25. Purification and characterization of eosinophil cationic protein from normal human eosinophils
26. Myeloperoxidase-mediated iodination in granulocytes
27. Eosinophil cationic protein (ECP): Molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease
28. Eosinophil cationic proteins (ECP and EPX) in health and disease
29. Analysis of the peptide subunits of human neutrophil myeloperoxidase
30. Releasability of human hypereosinophilic eosinophils is related to the density of the cells
31. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo
32. Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis
33. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion
34. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis